ArticleAntimicrobial agents and chemotherapy2017
Carbapenem-Resistant Pseudomonas aeruginosa Bacteremia: Risk Factors for Mortality and Microbiologic Treatment Failure.
Article in Antimicrobial agents and chemotherapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 2 syntheses or guidelines pooled it, 118 citations in OpenAlex.
- Global prevalence and antibiotic resistance profiles of carbapenem-resistantFrontiers in microbiology · 2025Pooled it
- Efficiency of combination therapy versus monotherapy for the treatment of infections due to carbapenem-resistant Gram-negative bacteria: a systematic review and meta-analysis.Systematic reviews · 2024Pooled it
- Beyond Resistance Genes:Life (Basel, Switzerland) · 2026Review
- Carbapenem-resistant Gram-negative bacilli infections in Japanese patients with cancer.Scientific reports · 2026Observational
- Predictors of Mortality inPathogens (Basel, Switzerland) · 2026Review
- Whole-genome sequencing reveals molecular characterization of carbapenem-resistantFrontiers in cellular and infection microbiology · 2026Article
- Early risk stratification for carbapenem resistance amongFrontiers in cellular and infection microbiology · 2026Article
- Coexistence of Multidrug Resistance and Hypervirulence-Associated Genes in Clinical Carbapenem-ResistantJournal of microbiology and biotechnology · 2025Article
- Outbreak of New Delhi metallo-β-lactamase carbapenemase-producing Pseudomonas aeruginosa infections in a Southern California hospital.American journal of infection control · 2025Article
- Carbapenem-resistant bacteria in the environment.Arhiv za higijenu rada i toksikologiju · 2025Review
- Molecular epidemiology and patient outcome of carbapenem-resistantJAC-antimicrobial resistance · 2025Article
- Antimicrobial Resistance and Mortality in Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2025Article
- Clinical Characteristics, Risk Factors and Prognosis of Carbapenem-ResistantInfection and drug resistance · 2025Article
- Antibacterial activity and mechanism of Sodium houttuyfonate against heteroresistantFrontiers in microbiology · 2025Article
- Antimicrobial Resistance Patterns and Epidemiological Distribution of Pathogenic Bacteria in the Pediatric Intensive Care Unit at Beijing Children's Hospital: A Decade-Long Retrospective Analysis (2014-2023).Infection and drug resistance · 2025Article
- Molecular characteristics and antibiotic resistance mechanisms of multidrug-resistant Pseudomonas aeruginosa in Nanning, China.BMC microbiology · 2024Article
- Hospital and municipal wastewater as a source of carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa in the environment: a review.Environmental science and pollution research international · 2024Review
- Impact of multidrug resistance on the virulence and fitness of Pseudomonas aeruginosa: a microbiological and clinical perspective.Infection · 2024Review
- Successful Treatment of an AML Patient Infected with Hypervirulent ST463 Pseudomonas Aeruginosa Harboring Rare Carbapenem-Resistant Genes blaAFM-1 and blaKPC-2 Following Allogeneic Hematopoietic Stem Cell Transplantation.Infection and drug resistance · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
We reviewed 37 patients treated for bacteremia due to carbapenem-resistant (CR) Pseudomonas aeruginosa Although 65% of isolates were multiple-drug resistant, therapeutic options were available, as all were susceptible to ≥1 antibiotic. A total of 92% of patients received active antimicrobial therapy, but only 57% received early active therapy (within 48 h). Fourteen-day mortality was 19%. Microbiologic failure occurred in 29%. The Pitt bacteremia score (P = 0.046) and delayed active therapy (P = 0.027) were predictive of death and microbiologic failure, respectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.